Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
Contact Us | Free E-Mail Updates | Journals | Register a colleague
Doctor's Guide Free CME
Congress Resource Centre

   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition

Warning | Privacy


 Recent news - Schizophrenia
    TopAbstracts in Schizophrenia 05/23/2013 - (DGNews)
    TopAbstracts in Schizophrenia 04/25/2013 - (DGNews)
    TopAbstracts in Schizophrenia 04/11/2013 - (DGNews)
    TopAbstracts in Schizophrenia 03/28/2013 - (DGNews)

    News archive

     Recent webcasts/CME - Schizophrenia
      Real World Management of Schizophrenia in the Comorbid Patient
      Practical Dosing Strategies in the Treatment of Schizophrenia

      Webcasts/CME archive

       Recent cases - Schizophrenia
        Severe Hyperglycemia Induced by Olanzapine was Improved with a Recovery of Insulin Secretion after Switching to Risperidone and Introducing Insulin Therapy
        The Insulin Sparing Effect of Telmisartan in a Case of Type 2 Diabetes Mellitus Associated with Schizophrenia under Treatment of Risperidone
        Graves' Disease Presenting as Paranoid Schizophrenia in a Nigerian Woman: A Case Report
        Schizophrenia-Like Psychosis Following Left Putamen Infarct: A Case Report
        Localisation Using Mini C-Arm Fluoroscopy of Needles Ingested by a Woman with Schizophrenia: A Case Report

        Cases archive

        my personal edition > schizophrenia > news

          E-Mail this DGDispatch to a colleague


        Reducing Dose of Antipsychotic Drug May Improve Cognitive Function in Patients With Schizophrenia: Presented at AAGP

        By Nancy A. Melville

        LOS ANGELES -- March 19, 2013 -- A reduction in the dose of antipsychotic therapy shows efficacy in reducing cognitive impairment in adults age 50 years and older with schizophrenia, according to results of a pilot study presented at the 2013 Annual Meeting of the American Association for Geriatric Psychiatry (AAGP).

        Cognitive impairment is a key symptom of schizophrenia, and the dopamine receptor blockade by antipsychotic drugs taken by patients with schizophrenia is believed to contribute to cognitive impairment.

        Researchers in previous studies have shown that patients with schizophrenia who have an estimated dopamine D2/3 receptor (D2/3R) occupancy by antipsychotics of 78% or higher demonstrated significantly more cognitive impairment -- particularly in the area of attention -- than did those with lower occupancy levels.

        Shinichiro Nakajima, MD, PhD, Centre for Addiction and Mental Health, Toronto, Ontario, and colleagues evaluated data on 8 patients (4 female) aged 50 years or more from a prospective antipsychotic dose-reduction positron-emission tomography (PET) study in individuals with schizophrenia. He presented the results here on March 15.

        The subjects had been clinically stable and were on oral risperidone at a steady dose of 2 mg/day or higher for at least 6 months.

        The mean dose of the antipsychotic drug risperidone was decreased from 3.4 1.6 mg/day to 2.4 1.0 mg/day (P <.001), and D2/3R occupancy in the putamen decreased from 73 8% to 62 11% (P = 0.018), with a median change in occupancy of 9%.

        The subjects next were divided into 2 groups denoting large and small changes in D2/3R occupancy, which was assessed by PET scan before and after the dose reduction; they were then compared on cognitive measures. Using a median split, the large and small D2/3R occupancy-change groups demonstrated changes in occupancy of 19.2 6.9% and 2.6 1.8%, respectively.

        The 2 groups only differed in duration of illness (small- vs large-change group: 28 6 years vs 37 5 years; P = 0.04).

        The large-change group experienced a significantly greater improvement in terms of cognition in the attention-task scores (Stroop Neuropsychological Screening Test 2) than did the small-change group: 10.8 11.5 versus -2.8 6.7 (P = 0.042).

        No other differences were observed in any other cognitive measure.

        "These preliminary results confirm and extend the current literature on the relationship between D2/3R blockade and deficits in attention among individuals with schizophrenia, by demonstrating this relationship in a longitudinal study design," the authors concluded.

        "The [results] also suggest that these deficits are potentially reversible with appropriate dosing," they added.

        [Presentation title: Improvement in Attention after Antipsychotic Dose Reduction in Late-life Schizophrenia: A Pilot PET-Cognition Study. Abstract EI 83]

        E-Mail this DGDispatch to a colleague   To print, use this version

        All contents Copyright (c) 1995-2018 Doctor's Guide Publishing Limited. All rights reserved.

        The NTK initiative. Physicians helping physicians identify Need-To-Know science
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.